Voya Investment Management LLC Decreases Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

Voya Investment Management LLC cut its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 71.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 22,016 shares of the company's stock after selling 54,849 shares during the period. Voya Investment Management LLC's holdings in Kura Oncology were worth $192,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of KURA. Marshall Wace LLP purchased a new position in shares of Kura Oncology in the fourth quarter worth approximately $8,265,000. Vanguard Group Inc. raised its position in Kura Oncology by 14.6% in the fourth quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company's stock worth $41,973,000 after acquiring an additional 615,211 shares during the period. Trexquant Investment LP boosted its stake in shares of Kura Oncology by 867.8% during the 4th quarter. Trexquant Investment LP now owns 566,945 shares of the company's stock worth $4,938,000 after acquiring an additional 508,362 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Kura Oncology by 463.4% during the 4th quarter. Renaissance Technologies LLC now owns 597,810 shares of the company's stock valued at $5,207,000 after acquiring an additional 491,700 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Kura Oncology by 35.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,425,960 shares of the company's stock valued at $12,419,000 after acquiring an additional 372,196 shares during the period.

Analyst Ratings Changes

Several analysts have issued reports on the company. Barclays cut their price target on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Kura Oncology in a report on Monday, April 28th. Cantor Fitzgerald raised shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. JMP Securities reissued a "market outperform" rating and issued a $28.00 price objective on shares of Kura Oncology in a research note on Tuesday, April 29th. Finally, UBS Group lowered their target price on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Kura Oncology currently has an average rating of "Moderate Buy" and an average price target of $23.89.

Kura Oncology Trading Down 4.8%

Shares of NASDAQ KURA opened at $5.80 on Wednesday. The stock has a market capitalization of $502.14 million, a P/E ratio of -2.46 and a beta of 0.50. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The business's 50 day moving average is $6.51 and its two-hundred day moving average is $9.01. Kura Oncology, Inc. has a 1-year low of $5.41 and a 1-year high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to the consensus estimate of $39.08 million. As a group, research analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.